Bringing science and development together through news and analysis

  • Gates gives US$60 million to microbicide research

The Bill & Melinda Gates Foundation announced this week that it will give US$60 million to research on microbicides — gels or creams designed to block the sexual transmission of HIV.

The grant will be made to the US-based International Partnership for Microbicides (IPM), an organisation set up last year with a US$15 million grant from the Rockefeller Foundation to accelerate the development of microbicides.

The IPM aims to encourage greater investment in microbicides — which so far have lacked support from major pharmaceutical companies — by providing targeted grants to both public and private organisations involved in microbicide research.

In exchange for IPM's support, microbicide developers must agree to provide their products at low cost in the developing world, where the need for microbicides is greatest.

"The Gates Foundation's injection of new resources will make industry sit up and take notice," says Craig Wheeler, president of Chiron BioPharmaceuticals. "IPM has essentially been transformed into a US$100-million venture capital fund. This will certainly draw many new entrants into microbicide research."

© SciDev.Net 2003

Related external links:

Bill & Melinda Gates Foundation
International Partnership for Microbicides
We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
  1. You have to credit our authors.
  2. You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
  5. The easiest way to get the article on your site is to embed the code below.
For more information view our media page and republishing guidelines.